North America Human Microbiome Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The North American human microbiome market is projected to grow significantly, reaching approximately USD 2,811.82 million by 2031, up from USD 654.89 million in 2023, reflecting a compound annual growth rate (CAGR) of 20.0% from 2023 to 2031.

Executive Summary and Market Analysis

North America stands as the leading region for epigenetics and microbiome research, with the United States commanding the largest market share, followed by Canada. The growth of the human microbiome market in this region is driven by several factors, including extensive research initiatives, increased funding for biotechnology, heightened health awareness among consumers, and a growing demand for probiotics and prebiotics aimed at managing chronic diseases. Additionally, there is a strong emphasis on developing microbiome-based therapeutics, an increase in relevant conferences, and the presence of key local players, all of which are expected to enhance market growth and revenue generation.

Market Segmentation Analysis

The North American human microbiome market can be segmented by type, application, and disease type:

Type: The market is divided into products and software/services, with products holding a larger market share in 2023. The product segment is further categorized into probiotics and prebiotics.
Application: The market is segmented into therapeutics, diagnostics, and research, with therapeutics dominating the market share in 2023.
Disease Type: The market is classified into categories such as obesity, diabetes, autoimmune disorders, cancer, gastrointestinal (GIT) issues, and others, with GIT issues leading the market in 2023.

Market Outlook

Government initiatives and support programs play a crucial role in the growth of the human microbiome market. Substantial funding and grants are often allocated for microbiome research, which accelerates the development of new treatments, devices, and diagnostics. For example, the National Institutes of Health (NIH) has committed USD 115 million over five years to support the Human Microbiome Project, which aims to enhance understanding of human health and improve disease prevention, diagnosis, and treatment. Such funding fosters innovation and commercialization, particularly for startups and small-to-medium enterprises (SMEs) in the microbiome sector. Furthermore, the establishment of regulatory frameworks for microbiome-based products can streamline the introduction of new treatments, ensuring safety and efficacy, which in turn boosts consumer confidence and market acceptance.

Country Insights

The North American human microbiome market includes the United States, Canada, and Mexico, with the US holding the largest market share in 2023. The application of microbiome research is rapidly expanding within biotechnology, emerging as a vital therapeutic approach for various chronic diseases. This has led to increased private investment and advancements in environmental microbiome engineering. Over the past decade, the US has invested around USD 1 billion in human microbiome research, with approximately 20% of this funding directed towards the Human Microbiome Project (HMP). Launched in 2007, the HMP aims to create essential research resources for studying the human microbiome, resulting in significant contributions to microbiome research and therapy development.

Recent Developments

The demand for human microbiome therapeutics in the US is further fueled by product launches and regulatory approvals. For instance, in November 2022, Ferring Pharmaceuticals received FDA approval for REBYOTA, a first-in-class microbiota-based live biotherapeutic designed to prevent recurrent Clostridioides difficile infections in adults following antibiotic treatment.

Company Profiles

Key players in the human microbiome market include MaaT Pharma, Ferring Holdings SA, AOBiome Therapeutics Inc, Finch Therapeutics Group Inc, Seres Therapeutics Inc, Merck & Co Inc, Rebiotix, Inc., Yakult Honsha Co., Ltd., IFF Nutrition & Biosciences, and Synthetic Biologics, Inc. These companies are pursuing various strategies such as market expansion, product innovation, and mergers and acquisitions to enhance their offerings and increase market share.

Product Code: TIPRE00003319

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. North America Human Microbiome Market Landscape

4.1 Overview
4.2 PEST Analysis

5. North America Human Microbiome Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Significant Investments by Key Market Players
- 5.1.2 Government Initiatives
5.2 Market Restraints
- 5.2.1 Challenges During Production of Microbiome
5.3 Market Opportunities
- 5.3.1 Robust Investment in Research and Development
5.4 Future Trends
- 5.4.1 Emergence of Precision Medicine
5.5 Impact of Drivers and Restraints:

6. North America Human Microbiome Market - Analysis

6.1 North America Human Microbiome Market Revenue (US$ Million), 2021-2031
6.2 North America Human Microbiome Market Forecast Analysis

7. North America Human Microbiome Market Analysis - by Type

7.1 Product
- 7.1.1 Overview
- 7.1.2 Product: North America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Software and Services
- 7.2.1 Overview
- 7.2.2 Software and Services: North America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. North America Human Microbiome Market Analysis - by Application

8.1 Therapeutics
- 8.1.1 Overview
- 8.1.2 Therapeutics: North America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Diagnostics
- 8.2.1 Overview
- 8.2.2 Diagnostics: North America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Research
- 8.3.1 Overview
- 8.3.2 Research: North America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. North America Human Microbiome Market Analysis - by Disease Type

9.1 Obesity
- 9.1.1 Overview
- 9.1.2 Obesity: North America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Diabetes
- 9.2.1 Overview
- 9.2.2 Diabetes: North America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Autoimmune Disorder
- 9.3.1 Overview
- 9.3.2 Autoimmune Disorder: North America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.4 Cancer
- 9.4.1 Overview
- 9.4.2 Cancer: North America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.5 GIT
- 9.5.1 Overview
- 9.5.2 GIT: North America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.6 Others
- 9.6.1 Overview
- 9.6.2 Others: North America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. North America Human Microbiome Market - Country Analysis

10.1 North America
- 10.1.1 North America Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.1 North America Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.2 United States: North America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.2.1 United States: North America Human Microbiome Market Share - by Type
    - 10.1.1.2.2 United States: North America Human Microbiome Market Share - by Product
    - 10.1.1.2.3 United States: North America Human Microbiome Market Share - by Application
    - 10.1.1.2.4 United States: North America Human Microbiome Market Share - by Disease Type
  - 10.1.1.3 Canada: North America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.3.1 Canada: North America Human Microbiome Market Share - by Type
    - 10.1.1.3.2 Canada: North America Human Microbiome Market Share - by Product
    - 10.1.1.3.3 Canada: North America Human Microbiome Market Share - by Application
    - 10.1.1.3.4 Canada: North America Human Microbiome Market Share - by Disease Type
  - 10.1.1.4 Mexico: North America Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.1.4.1 Mexico: North America Human Microbiome Market Share - by Type
    - 10.1.1.4.2 Mexico: North America Human Microbiome Market Share - by Product
    - 10.1.1.4.3 Mexico: North America Human Microbiome Market Share - by Application
    - 10.1.1.4.4 Mexico: North America Human Microbiome Market Share - by Disease Type

11. Competitive Landscape

11.1 Heat Map Analysis by Key Players
11.2 Company Positioning and Concentration

12. Industry Landscape

12.1 Overview
12.2 Growth Strategies in the Human Microbiome Market
12.3 Organic Growth Strategies
- 12.3.1 Overview
12.4 Inorganic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Ferring Holdings SA
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 AOBiome Therapeutics Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Finch Therapeutics Group Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Financial Overview
- 13.4.4 SWOT Analysis
- 13.4.5 Key Developments
13.5 Seres Therapeutics Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Merck & Co Inc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Yakult Honsha Co., Ltd.
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Rebiotix, Inc.
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 IFF Nutrition & Biosciences
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Synthetic Biologics, Inc.
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 About Us
14.2 List of Abbreviations